Aberrant expression of BCL2A1-restricted minor histocompatibility antigens in melanoma cells: Application for allogeneic transplantation

Keyphrases

• Aberrant Expression 100%
• Melanoma Cells 100%
• Minor Histocompatibility Antigens 100%
• Allogeneic Transplantation 100%
• BCL2A1 100%
• HA-1 40%
• Cytotoxic T Lymphocytes 20%
• Graft-versus-leukemia Effect 20%
• Solid Tumors 20%
• Melanoma Patients 20%
• Renal Cancer 20%
• Primary Melanoma 20%
• Target Organ 20%
• Melanoma 20%
• Tumor Regression 20%
• Hematopoietic Cells 20%
• Real-time PCR Analysis 20%
• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 20%
• Therapeutic Potential 20%
• Metastatic Tumor 20%

Medicine and Dentistry

• Melanoma Cell 100%
• Allotransplantation 100%
• Minor Histocompatibility Antigen 100%
• Melanoma Cell Line 40%
• Graft Versus Host Reaction 40%
• Nodular Melanoma 40%
• Solid Malignant Neoplasm 40%
• Hematopoietic Stem Cell 20%
• Graft Versus Tumor Effect 20%
• Kidney Cancer 20%
• Cytotoxic T-Cell 20%
• Real Time Polymerase Chain Reaction 20%
• Target Organ 20%
• Allogeneic Hematopoietic Stem Cell Transplantation 20%
• Tumor Regression 20%

Immunology and Microbiology

• Minor Histocompatibility Antigen 100%
• Allotransplantation 100%
• Melanoma Cell 100%
• Melanoma Cell Line 40%
• Graft-Versus-Host Disease 40%
• Graft Versus Tumor Effect 20%
• Tumor Cell 20%
• Cytotoxic T Cell 20%
• Hematopoietic Cell 20%
• Target Organ 20%
• Allogeneic Hematopoietic Stem Cell Transplantation 20%